GL1X · GenesisL1 explorer

MolNFT v1 · #160310 · protein

Crystal structure of human KRAS G12C covalently bound to a quinazolinone inhibitor

6PGP · GTPase KRAS: “Crystal structure of human KRAS G12C covalently bound to a quinazolinone inhibitor”. X-ray diffraction, 3 ligands (GDP, OHY, CA), 5 pockets (best druggability 0.65). MolNFT v1 #160310 on GenesisL1: 3D structure…

PDB
6PGP
Type
protein
Length
338 residues
Chains
2
Method
x-ray diffraction
Collection
MolNFT v1 / PDB
Contract
0xDE3723766Bc32dcACD03C17BaA400A7B36837Eba
Owner
0x3396CDB397284571d12822B4ae1189a8E22AAAAA
Molecule
GTPase KRAS
UniProt
P01116
Ligands
GDP, OHY, CA
Pockets
5 · best druggability 0.65

Structure

x-ray diffraction · 1 distinct chain · 38% helix, 25% strand (DSSP).

ChainMoleculeTypeResiduesSecondary structureUniProt
A, BGTPase KRASprotein16938% helix, 25% strandP01116

Ligands and binding sites

  • GDP · Guanosine-5'-diphosphate · ligand · 2 copies · chains A, B
  • OHY · 6-chloro-7-(2-fluoro-6-hydroxyphenyl)-4-(4-propanoylpiperazin-1-yl)-1-[2-(propan-2-yl) phenyl]quinazolin-2(1H)-one · ligand · 2 copies · chains A, B
  • CA · Calcium ion · metal · 4 copies · chains A, B

Binding sites are the residues within 4.5 Å of a ligand's heavy atoms.

Pockets

5 pockets found on a 1 Å grid, 4 with a druggability of 0.5 or more.

PocketVolume (ų)DruggabilityBuriednessLining residuesInside
13490.650.8047GDP, CA, OHY
23610.650.7946GDP, CA, OHY
31530.600.8426empty
41570.520.7926empty
5540.310.7617empty

Interfaces

1 interface between chains.

  • A–B · 482 Ų buried · 3 hydrogen bonds · protein-protein

Modifications

Observed in the structure: 2 covalent (covalent ligand).

Compared structures

  • 6PGP · Crystal structure of human KRAS G12C covalently bound to a quinazoli inhibitor · the same entry in another collection · chain A against A, TM-score 1.00

Analyse

GL1X is a live explorer of the GenesisL1 blockchain. Turn on JavaScript for search, charts and interactive views.